Log in

NASDAQ:PLRXLegend Biotech Stock Price, Forecast & News

+0.23 (+0.78 %)
(As of 07/3/2020 04:00 PM ET)
Today's Range
Now: $29.53
50-Day Range N/A
52-Week Range
Now: $29.53
Volume78,300 shs
Average Volume249,833 shs
Market Capitalization$1.01 billion
P/E RatioN/A
Dividend YieldN/A
Pliant Therapeutics, Inc., a biotechnology company, discovers, develops, and commercializes treatments for fibrotic diseases. The company focuses on tissue-specific integrin modulation and EMT inhibition fibrosis diseases in lungs, liver, muscle, kidney, skin, heart, and the gastrointestinal tract. Its pipeline includes PLN-74809, an inhibitor of aVß1/aVß6 for idiopathic pulmonary fibrosis and primary sclerosing cholangitis; and PLN-1474, an inhibitor of TGF-ß activation by the integrin aVß1 for the treatment of end-stage liver fibrosis in NASH. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.7 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.84 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:PLRX



Sales & Book Value

Annual SalesN/A



Market Cap$1.01 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive PLRX News and Ratings via Email

Sign-up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter.

Legend Biotech (NASDAQ:PLRX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Legend Biotech?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Legend Biotech in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Legend Biotech.

What price target have analysts set for PLRX?

4 brokers have issued 1-year price targets for Legend Biotech's stock. Their forecasts range from $40.00 to $50.00. On average, they expect Legend Biotech's stock price to reach $43.33 in the next year. This suggests a possible upside of 46.7% from the stock's current price. View analysts' price targets for Legend Biotech.

Has Legend Biotech been receiving favorable news coverage?

News coverage about PLRX stock has trended somewhat positive on Saturday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Legend Biotech earned a coverage optimism score of 1.9 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Legend Biotech.

Who are some of Legend Biotech's key competitors?

Who are Legend Biotech's key executives?

Legend Biotech's management team includes the following people:
  • Prof. Bernard Coulie M.B.A., Ph.D., M.D., MBA, Pres, CEO & Director (Age 54, Pay $699.21k)
  • Dr. Keith Lamont Cummings M.B.A., M.D., Chief Financial Officer (Age 43, Pay $725.6k)
  • Mr. Johannes P. Hull, Chief Bus. Officer (Age 45, Pay $577.71k)
  • Dr. Rik Derynck, Scientific Founder & Member of Scientific Advisory Board
  • Mr. Dean Sheppard M.D., Scientific Founder & Member of Scientific Advisory Board

When did Legend Biotech IPO?

(PLRX) raised $90 million in an initial public offering on Wednesday, June 3rd 2020. The company issued 6,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler acted as the underwriters for the IPO and Needham & Company was co-manager.

What is Legend Biotech's stock symbol?

Legend Biotech trades on the NASDAQ under the ticker symbol "PLRX."

When does Legend Biotech's quiet period expire?

Legend Biotech's quiet period expires on Monday, July 13th. Legend Biotech had issued 9,000,000 shares in its IPO on June 3rd. The total size of the offering was $144,000,000 based on an initial share price of $16.00. During Legend Biotech's quiet period, insiders and underwriters involved in the IPO are prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of Legend Biotech?

Shares of PLRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Legend Biotech's stock price today?

One share of PLRX stock can currently be purchased for approximately $29.53.

How big of a company is Legend Biotech?

Legend Biotech has a market capitalization of $1.01 billion. Legend Biotech employs 62 workers across the globe.

What is Legend Biotech's official website?

The official website for Legend Biotech is pliantrx.com.

How can I contact Legend Biotech?

Legend Biotech's mailing address is 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-481-6770 or via email at [email protected]

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.